- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT04628767
Testen van de toevoeging van MEDI4736 (Durvalumab) aan chemotherapie vóór een operatie voor patiënten met hooggradige kanker van de bovenste urinewegen
Een fase II/III-studie van MEDI4736 (Durvalumab) en chemotherapie voor patiënten met hooggradige urotheelkanker van de bovenste tractus vóór nefrouterectomie
This phase II/III trial compares the effect of adding durvalumab to chemotherapy versus chemotherapy alone before surgery in treating patients with upper urinary tract cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as methotrexate, vinblastine, doxorubicin, cisplatin, and gemcitabine work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Durvalumab in combination with chemotherapy before surgery may enhance the shrinking of the tumor compared to chemotherapy alone.
Studie Overzicht
Toestand
Interventie / Behandeling
- Geneesmiddel: Cisplatin
- Procedure: Biospecimen Collection
- Geneesmiddel: Methotrexate
- Procedure: Computed Tomography
- Procedure: Magnetic Resonance Imaging
- Geneesmiddel: Gemcitabine Hydrochloride
- Procedure: Therapeutic Conventional Surgery
- Procedure: Biopsy Procedure
- Biologisch: Durvalumab
- Geneesmiddel: Doxorubicin Hydrochloride
- Biologisch: Pegfilgrastim
- Geneesmiddel: Vinblastine Sulfate
Gedetailleerde beschrijving
PRIMARY OBJECTIVES:
I. To compare event-free survival (EFS) between patients with upper tract urothelial cancer (UTUC) randomized to neoadjuvant accelerated methotrexate, vinblastine, Adriamycin, cisplatin (aMVAC) alone or in combination with durvalumab. (Cisplatin eligible patients [Arms A and B]) II. Evaluation of pathologic complete response at radical nephroureterectomy (RNU) (pathologic complete response [pCR], ypT0N0/Nx). (Cisplatin ineligible patients [Arm C]).
SECONDARY OBJECTIVES:
I. To assess pathologic complete response (pCR) at surgery. (Cisplatin eligible cohort) II. Event-free survival (EFS) will be evaluated for the cisplatin ineligible cohort as a secondary endpoint. (Cisplatin ineligible cohort) III. Overall survival in all, and by post chemotherapy response (ypT0N0, yp =< T1N0, yp >= T2Nany). (All patients) IV. To evaluate disease-free survival (DFS) in each arm of the trial separately. (All patients) V. To evaluate cancer-specific survival of patients in each arm of the trial separately. (All patients) VI. To evaluate renal function outcomes following systemic treatment and following surgery ([RNU) in each arm of the trial separately. (All patients) VII. To evaluate safety and tolerability of neoadjuvant aMVAC alone or in combination with durvalumab prior to RNU. (All patients)
OUTLINE: Patients eligible for cisplatin are randomized to Arms A or B. Patients ineligible for cisplatin are assigned to Arm C.
ARM A: Patients receive durvalumab intravenously (IV) over 60 minutes on day 1 of chemotherapy cycles 1 and 3. Patients also receive methotrexate IV over 2-3 minutes, vinblastine sulfate IV, doxorubicin IV, cisplatin IV over at least 2 hours on day 1. Treatments repeat every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment, patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery.
ARM B: Patients also receive methotrexate IV over 2-3 minutes, vinblastine sulfate IV, doxorubicin IV, cisplatin IV over at least 2 hours on day 1. Treatments repeat every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment, patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery.
ARM C: Patients receive durvalumab IV over 60 minutes on day 1 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery.
Patients also undergo tissue biopsy and blood sample collection on study, and computed tomography (CT) or magnetic resonance imaging (MRI) throughout the trial.
After completion of study treatment, patients are followed up within 30 days and then every 3-6 months for up to 5 years from study entry.
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
- Fase 3
Contacten en locaties
Studie Locaties
-
-
Arizona
-
Kingman, Arizona, Verenigde Staten, 86401
- Werving
- Kingman Regional Medical Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 702-384-0013
- E-mail: research@sncrf.org
-
Hoofdonderzoeker:
- Khawaja S. Jahangir
-
-
Arkansas
-
Fort Smith, Arkansas, Verenigde Staten, 72903
- Geschorst
- Mercy Hospital Fort Smith
-
Little Rock, Arkansas, Verenigde Staten, 72205
- Actief, niet wervend
- University of Arkansas for Medical Sciences
-
-
California
-
Auburn, California, Verenigde Staten, 95602
- Actief, niet wervend
- Sutter Auburn Faith Hospital
-
Berkeley, California, Verenigde Staten, 94704
- Actief, niet wervend
- Alta Bates Summit Medical Center-Herrick Campus
-
Duarte, California, Verenigde Staten, 91010
- Actief, niet wervend
- City of Hope Comprehensive Cancer Center
-
Fremont, California, Verenigde Staten, 94538
- Actief, niet wervend
- Palo Alto Medical Foundation-Fremont
-
La Jolla, California, Verenigde Staten, 92093
- Werving
- UC San Diego Moores Cancer Center
-
Hoofdonderzoeker:
- Aditya Bagrodia
-
Contact:
- Site Public Contact
- Telefoonnummer: 858-822-5354
- E-mail: cancercto@ucsd.edu
-
Modesto, California, Verenigde Staten, 95355
- Actief, niet wervend
- Memorial Medical Center
-
Mountain View, California, Verenigde Staten, 94040
- Actief, niet wervend
- Palo Alto Medical Foundation-Camino Division
-
Palo Alto, California, Verenigde Staten, 94304
- Werving
- Stanford Cancer Institute Palo Alto
-
Hoofdonderzoeker:
- Ali R. Khaki
-
Contact:
- Site Public Contact
- Telefoonnummer: 650-498-7061
- E-mail: cancertrialsinfo@stanford.edu
-
Palo Alto, California, Verenigde Staten, 94301
- Actief, niet wervend
- Palo Alto Medical Foundation Health Care
-
Roseville, California, Verenigde Staten, 95661
- Actief, niet wervend
- Sutter Roseville Medical Center
-
Sacramento, California, Verenigde Staten, 95816
- Actief, niet wervend
- Sutter Medical Center Sacramento
-
San Diego, California, Verenigde Staten, 92103
- Werving
- UC San Diego Medical Center - Hillcrest
-
Hoofdonderzoeker:
- Aditya Bagrodia
-
Contact:
- Site Public Contact
- E-mail: rhabbaba@health.ucsd.edu
-
San Francisco, California, Verenigde Staten, 94115
- Actief, niet wervend
- California Pacific Medical Center-Pacific Campus
-
Santa Cruz, California, Verenigde Staten, 95065
- Actief, niet wervend
- Palo Alto Medical Foundation-Santa Cruz
-
Santa Rosa, California, Verenigde Staten, 95403
- Actief, niet wervend
- Sutter Pacific Medical Foundation
-
Sunnyvale, California, Verenigde Staten, 94086
- Actief, niet wervend
- Palo Alto Medical Foundation-Sunnyvale
-
Vallejo, California, Verenigde Staten, 94589
- Actief, niet wervend
- Sutter Solano Medical Center/Cancer Center
-
-
Colorado
-
Aurora, Colorado, Verenigde Staten, 80045
- Werving
- UCHealth University of Colorado Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 720-848-0650
-
Hoofdonderzoeker:
- Elizabeth R. Kessler
-
Denver, Colorado, Verenigde Staten, 80206
- Geschorst
- UCHealth - Cherry Creek
-
Fort Collins, Colorado, Verenigde Staten, 80524
- Werving
- Poudre Valley Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 970-297-6150
-
Hoofdonderzoeker:
- Elizabeth R. Kessler
-
Fort Collins, Colorado, Verenigde Staten, 80528
- Werving
- Cancer Care and Hematology-Fort Collins
-
Contact:
- Site Public Contact
- E-mail: ecog.rss@jimmy.harvard.edu
-
Hoofdonderzoeker:
- Elizabeth R. Kessler
-
Greeley, Colorado, Verenigde Staten, 80631
- Werving
- UCHealth Greeley Hospital
-
Contact:
- Site Public Contact
- E-mail: ecog.rss@jimmy.harvard.edu
-
Hoofdonderzoeker:
- Elizabeth R. Kessler
-
Highlands Ranch, Colorado, Verenigde Staten, 80129
- Werving
- UCHealth Highlands Ranch Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 720-848-0650
-
Hoofdonderzoeker:
- Elizabeth R. Kessler
-
Lone Tree, Colorado, Verenigde Staten, 80124
- Werving
- UCHealth Lone Tree Health Center
-
Contact:
- Site Public Contact
- E-mail: ecog.rss@jimmy.harvard.edu
-
Hoofdonderzoeker:
- Elizabeth R. Kessler
-
Loveland, Colorado, Verenigde Staten, 80538
- Werving
- Medical Center of the Rockies
-
Contact:
- Site Public Contact
- Telefoonnummer: 970-203-7083
-
Hoofdonderzoeker:
- Elizabeth R. Kessler
-
-
District of Columbia
-
Washington D.C., District of Columbia, Verenigde Staten, 20016
- Werving
- Sibley Memorial Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 202-243-2373
- E-mail: jquiver1@jhmi.edu
-
Hoofdonderzoeker:
- Jean H. Hoffman-Censits
-
Washington D.C., District of Columbia, Verenigde Staten, 20010
- Werving
- MedStar Washington Hospital Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 202-877-8839
-
Hoofdonderzoeker:
- Suthee Rapisuwon
-
-
Florida
-
Jacksonville, Florida, Verenigde Staten, 32224-9980
- Actief, niet wervend
- Mayo Clinic in Florida
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30322
- Werving
- Emory University Hospital/Winship Cancer Institute
-
Contact:
- Site Public Contact
- Telefoonnummer: 404-778-1868
-
Hoofdonderzoeker:
- Jacqueline T. Brown
-
Atlanta, Georgia, Verenigde Staten, 30308
- Werving
- Emory University Hospital Midtown
-
Contact:
- Site Public Contact
- Telefoonnummer: 888-946-7447
-
Hoofdonderzoeker:
- Jacqueline T. Brown
-
Atlanta, Georgia, Verenigde Staten, 30342
- Werving
- Emory Saint Joseph's Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 404-851-7115
-
Hoofdonderzoeker:
- Jacqueline T. Brown
-
Decatur, Georgia, Verenigde Staten, 30033
- Werving
- Emory Decatur Hospital
-
Hoofdonderzoeker:
- Jacqueline T. Brown
-
Contact:
- Site Public Contact
- Telefoonnummer: 440-778-1868
- E-mail: clinicaltrialsoncology@dekalbmedical.org
-
-
Idaho
-
Nampa, Idaho, Verenigde Staten, 83687
- Werving
- Saint Alphonsus Cancer Care Center-Nampa
-
Contact:
- Site Public Contact
- Telefoonnummer: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Hoofdonderzoeker:
- Elie G. Dib
-
-
Illinois
-
Alton, Illinois, Verenigde Staten, 62002
- Geschorst
- OSF Saint Anthony's Health Center
-
Barrington, Illinois, Verenigde Staten, 60010
- Werving
- Advocate Good Shepherd Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 847-842-4847
-
Hoofdonderzoeker:
- Thomas J. Saphner
-
Bloomington, Illinois, Verenigde Staten, 61704
- Actief, niet wervend
- Illinois CancerCare-Bloomington
-
Burr Ridge, Illinois, Verenigde Staten, 60527
- Actief, niet wervend
- Loyola Center for Health at Burr Ridge
-
Canton, Illinois, Verenigde Staten, 61520
- Actief, niet wervend
- Illinois CancerCare-Canton
-
Carbondale, Illinois, Verenigde Staten, 62902
- Geschorst
- Memorial Hospital of Carbondale
-
Carterville, Illinois, Verenigde Staten, 62918
- Werving
- SIH Cancer Institute
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 618-985-3333
- E-mail: clinical.research@sih.net
-
Carthage, Illinois, Verenigde Staten, 62321
- Actief, niet wervend
- Illinois CancerCare-Carthage
-
Centralia, Illinois, Verenigde Staten, 62801
- Geschorst
- Centralia Oncology Clinic
-
Chicago, Illinois, Verenigde Staten, 60657
- Werving
- Advocate Illinois Masonic Medical Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 773-296-5360
-
Hoofdonderzoeker:
- Thomas J. Saphner
-
Crystal Lake, Illinois, Verenigde Staten, 60014
- Werving
- AMG Crystal Lake - Oncology
-
Contact:
- Site Public Contact
- Telefoonnummer: 630-929-6129
- E-mail: advocateresearch@advocate.com
-
Hoofdonderzoeker:
- Thomas J. Saphner
-
Danville, Illinois, Verenigde Staten, 61832
- Werving
- Carle at The Riverfront
-
Hoofdonderzoeker:
- Prem Sobti
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-446-5532
- E-mail: Research@Carle.com
-
Decatur, Illinois, Verenigde Staten, 62526
- Werving
- Cancer Care Specialists of Illinois - Decatur
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 217-876-4762
- E-mail: morganthaler.jodi@mhsil.com
-
Decatur, Illinois, Verenigde Staten, 62526
- Geschorst
- Decatur Memorial Hospital
-
Dixon, Illinois, Verenigde Staten, 61021
- Actief, niet wervend
- Illinois CancerCare-Dixon
-
Downers Grove, Illinois, Verenigde Staten, 60515
- Werving
- Advocate Good Samaritan Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 630-275-1270
- E-mail: Barbara.barhamand@advocatehealth.com
-
Hoofdonderzoeker:
- Thomas J. Saphner
-
Effingham, Illinois, Verenigde Staten, 62401
- Werving
- Carle Physician Group-Effingham
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-446-5532
- E-mail: Research@carle.com
-
Hoofdonderzoeker:
- Prem Sobti
-
Effingham, Illinois, Verenigde Staten, 62401
- Werving
- Crossroads Cancer Center
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 217-876-4762
- E-mail: morganthaler.jodi@mhsil.com
-
Elgin, Illinois, Verenigde Staten, 60123
- Werving
- Advocate Sherman Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 847-429-2907
-
Hoofdonderzoeker:
- Thomas J. Saphner
-
Eureka, Illinois, Verenigde Staten, 61530
- Actief, niet wervend
- Illinois CancerCare-Eureka
-
Galesburg, Illinois, Verenigde Staten, 61401
- Geschorst
- Western Illinois Cancer Treatment Center
-
Galesburg, Illinois, Verenigde Staten, 61401
- Actief, niet wervend
- Illinois CancerCare-Galesburg
-
Hazel Crest, Illinois, Verenigde Staten, 60429
- Werving
- Advocate South Suburban Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 708-799-9995
-
Hoofdonderzoeker:
- Thomas J. Saphner
-
Homer Glen, Illinois, Verenigde Staten, 60491
- Actief, niet wervend
- Loyola Medicine Homer Glen
-
Kewanee, Illinois, Verenigde Staten, 61443
- Actief, niet wervend
- Illinois CancerCare-Kewanee Clinic
-
Libertyville, Illinois, Verenigde Staten, 60048
- Werving
- AMG Libertyville - Oncology
-
Contact:
- Site Public Contact
- Telefoonnummer: 630-929-6129
- E-mail: advocateresearch@advocatehealth.com
-
Hoofdonderzoeker:
- Thomas J. Saphner
-
Macomb, Illinois, Verenigde Staten, 61455
- Actief, niet wervend
- Illinois CancerCare-Macomb
-
Mattoon, Illinois, Verenigde Staten, 61938
- Werving
- Carle Physician Group-Mattoon/Charleston
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-446-5532
- E-mail: Research@carle.com
-
Hoofdonderzoeker:
- Prem Sobti
-
Maywood, Illinois, Verenigde Staten, 60153
- Actief, niet wervend
- Loyola University Medical Center
-
Melrose Park, Illinois, Verenigde Staten, 60160
- Actief, niet wervend
- Marjorie Weinberg Cancer Center at Loyola-Gottlieb
-
Mount Vernon, Illinois, Verenigde Staten, 62864
- Werving
- SSM Health Good Samaritan
-
Hoofdonderzoeker:
- Jay W. Carlson
-
Contact:
- Site Public Contact
- Telefoonnummer: 618-899-1894
- E-mail: gayla.hall@ssmhealth.com
-
O'Fallon, Illinois, Verenigde Staten, 62269
- Werving
- Cancer Care Center of O'Fallon
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 217-876-4762
- E-mail: morganthaler.jodi@mhsil.com
-
Oak Lawn, Illinois, Verenigde Staten, 60453-2699
- Werving
- Advocate Christ Medical Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-323-8622
-
Hoofdonderzoeker:
- Thomas J. Saphner
-
Ottawa, Illinois, Verenigde Staten, 61350
- Actief, niet wervend
- Illinois CancerCare-Ottawa Clinic
-
Park Ridge, Illinois, Verenigde Staten, 60068
- Werving
- Advocate Lutheran General Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 847-384-3621
-
Hoofdonderzoeker:
- Thomas J. Saphner
-
Pekin, Illinois, Verenigde Staten, 61554
- Actief, niet wervend
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Verenigde Staten, 61636
- Geschorst
- Methodist Medical Center of Illinois
-
Peoria, Illinois, Verenigde Staten, 61615
- Actief, niet wervend
- Illinois CancerCare-Peoria
-
Peru, Illinois, Verenigde Staten, 61354
- Geschorst
- Valley Radiation Oncology
-
Peru, Illinois, Verenigde Staten, 61354
- Actief, niet wervend
- Illinois CancerCare-Peru
-
Princeton, Illinois, Verenigde Staten, 61356
- Actief, niet wervend
- Illinois CancerCare-Princeton
-
Springfield, Illinois, Verenigde Staten, 62702
- Werving
- Southern Illinois University School of Medicine
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 217-545-7929
-
Springfield, Illinois, Verenigde Staten, 62702
- Werving
- Springfield Clinic
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-444-7541
-
Springfield, Illinois, Verenigde Staten, 62781
- Geschorst
- Springfield Memorial Hospital
-
Urbana, Illinois, Verenigde Staten, 61801
- Werving
- Carle Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-446-5532
- E-mail: Research@carle.com
-
Hoofdonderzoeker:
- Prem Sobti
-
Washington, Illinois, Verenigde Staten, 61571
- Actief, niet wervend
- Illinois CancerCare - Washington
-
-
Indiana
-
Richmond, Indiana, Verenigde Staten, 47374
- Actief, niet wervend
- Reid Health
-
-
Iowa
-
Ames, Iowa, Verenigde Staten, 50010
- Actief, niet wervend
- Mary Greeley Medical Center
-
Ames, Iowa, Verenigde Staten, 50010
- Actief, niet wervend
- McFarland Clinic - Ames
-
Bettendorf, Iowa, Verenigde Staten, 52722
- Werving
- University of Iowa Healthcare Cancer Services Quad Cities
-
Hoofdonderzoeker:
- Fernando Maciel Barbosa
-
Contact:
- Site Public Contact
- Telefoonnummer: 563-355-7733
- E-mail: katherine-daprile@uiowa.edu
-
Boone, Iowa, Verenigde Staten, 50036
- Actief, niet wervend
- McFarland Clinic - Boone
-
Fort Dodge, Iowa, Verenigde Staten, 50501
- Actief, niet wervend
- McFarland Clinic - Trinity Cancer Center
-
Iowa City, Iowa, Verenigde Staten, 52242
- Werving
- University of Iowa/Holden Comprehensive Cancer Center
-
Hoofdonderzoeker:
- Fernando Maciel Barbosa
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-237-1225
-
Jefferson, Iowa, Verenigde Staten, 50129
- Actief, niet wervend
- McFarland Clinic - Jefferson
-
Marshalltown, Iowa, Verenigde Staten, 50158
- Actief, niet wervend
- McFarland Clinic - Marshalltown
-
-
Kansas
-
Garden City, Kansas, Verenigde Staten, 67846
- Geschorst
- Central Care Cancer Center - Garden City
-
Great Bend, Kansas, Verenigde Staten, 67530
- Geschorst
- Central Care Cancer Center - Great Bend
-
-
Kentucky
-
Lexington, Kentucky, Verenigde Staten, 40536
- Werving
- University of Kentucky/Markey Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 859-257-3379
-
Hoofdonderzoeker:
- Patrick J. Hensley
-
-
Louisiana
-
Baton Rouge, Louisiana, Verenigde Staten, 70809
- Werving
- Mary Bird Perkins Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 225-215-1353
- E-mail: clinicalresearch@marybird.com
-
Hoofdonderzoeker:
- Victor T. Lin
-
Metairie, Louisiana, Verenigde Staten, 70006
- Werving
- East Jefferson General Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 504-210-3539
- E-mail: emede1@lsuhsc.edu
-
Hoofdonderzoeker:
- Rajasree P. Chowdry
-
Metairie, Louisiana, Verenigde Staten, 70006
- Werving
- LSU Healthcare Network / Metairie Multi-Specialty Clinic
-
Contact:
- Site Public Contact
- Telefoonnummer: 504-210-3539
- E-mail: emede1@lsuhsc.edu
-
Hoofdonderzoeker:
- Rajasree P. Chowdry
-
Metairie, Louisiana, Verenigde Staten, 70002
- Werving
- Mary Bird Perkins Cancer Center - Metairie
-
Hoofdonderzoeker:
- Victor T. Lin
-
Contact:
- Site Public Contact
- Telefoonnummer: 504-584-6990
-
New Orleans, Louisiana, Verenigde Staten, 70112
- Werving
- University Medical Center New Orleans
-
Contact:
- Site Public Contact
- Telefoonnummer: 504-210-3539
- E-mail: emede1@lsuhsc.edu
-
Hoofdonderzoeker:
- Rajasree P. Chowdry
-
-
Maine
-
Augusta, Maine, Verenigde Staten, 04330
- Werving
- Harold Alfond Center for Cancer Care
-
Contact:
- Site Public Contact
- Telefoonnummer: 207-626-4855
-
Hoofdonderzoeker:
- Erin Adler
-
Biddeford, Maine, Verenigde Staten, 04005
- Geschorst
- MaineHealth Maine Medical Center - Biddeford
-
Sanford, Maine, Verenigde Staten, 04073
- Werving
- MaineHealth Cancer Care Center of York County
-
Contact:
- Site Public Contact
- Telefoonnummer: 207-459-1600
-
Hoofdonderzoeker:
- Erin Adler
-
Sanford, Maine, Verenigde Staten, 04073
- Werving
- MaineHealth Cancer Care and IV Therapy - Sanford
-
Contact:
- Site Public Contact
- Telefoonnummer: 207-396-8670
- E-mail: clinicalresearch@mainehealth.org
-
Hoofdonderzoeker:
- Erin Adler
-
Scarborough, Maine, Verenigde Staten, 04074
- Werving
- MaineHealth Maine Medical Center- Scarborough
-
Contact:
- Site Public Contact
- Telefoonnummer: 207-396-8670
- E-mail: clinicalresearch@mainehealth.org
-
Hoofdonderzoeker:
- Erin Adler
-
South Portland, Maine, Verenigde Staten, 04106
- Werving
- MaineHealth Cancer Care and IV Therapy - South Portland
-
Contact:
- Site Public Contact
- Telefoonnummer: 207-396-8670
- E-mail: clinicalresearch@mainehealth.org
-
Hoofdonderzoeker:
- Erin Adler
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21287
- Werving
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 410-955-8804
- E-mail: jhcccro@jhmi.edu
-
Hoofdonderzoeker:
- Jean H. Hoffman-Censits
-
-
Massachusetts
-
Worcester, Massachusetts, Verenigde Staten, 01655
- Werving
- UMass Memorial Medical Center - University Campus
-
Contact:
- Site Public Contact
- Telefoonnummer: 508-856-3216
- E-mail: cancer.research@umassmed.edu
-
Hoofdonderzoeker:
- Kriti Mittal
-
-
Michigan
-
Ann Arbor, Michigan, Verenigde Staten, 48106
- Werving
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Contact:
- Site Public Contact
- Telefoonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hoofdonderzoeker:
- Elie G. Dib
-
Brighton, Michigan, Verenigde Staten, 48114
- Werving
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Contact:
- Site Public Contact
- Telefoonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hoofdonderzoeker:
- Elie G. Dib
-
Brighton, Michigan, Verenigde Staten, 48114
- Werving
- Trinity Health Medical Center - Brighton
-
Contact:
- Site Public Contact
- Telefoonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hoofdonderzoeker:
- Elie G. Dib
-
Canton, Michigan, Verenigde Staten, 48188
- Werving
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Contact:
- Site Public Contact
- Telefoonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hoofdonderzoeker:
- Elie G. Dib
-
Canton, Michigan, Verenigde Staten, 48188
- Werving
- Trinity Health Medical Center - Canton
-
Contact:
- Site Public Contact
- Telefoonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hoofdonderzoeker:
- Elie G. Dib
-
Chelsea, Michigan, Verenigde Staten, 48118
- Werving
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hoofdonderzoeker:
- Elie G. Dib
-
Chelsea, Michigan, Verenigde Staten, 48118
- Werving
- Chelsea Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hoofdonderzoeker:
- Elie G. Dib
-
Clarkston, Michigan, Verenigde Staten, 48346
- Werving
- Hematology Oncology Consultants-Clarkston
-
Contact:
- Site Public Contact
- Telefoonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hoofdonderzoeker:
- Elie G. Dib
-
Clarkston, Michigan, Verenigde Staten, 48346
- Geschorst
- Newland Medical Associates-Clarkston
-
Flint, Michigan, Verenigde Staten, 48503
- Werving
- Genesys Hurley Cancer Institute
-
Contact:
- Site Public Contact
- Telefoonnummer: 810-762-8038
- E-mail: wstrong@ghci.org
-
Hoofdonderzoeker:
- Elie G. Dib
-
Flint, Michigan, Verenigde Staten, 48503
- Werving
- Hurley Medical Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 810-762-8038
- E-mail: wstrong@ghci.org
-
Hoofdonderzoeker:
- Elie G. Dib
-
Flint, Michigan, Verenigde Staten, 48503
- Geschorst
- Genesee Hematology Oncology PC
-
Flint, Michigan, Verenigde Staten, 48503
- Werving
- Cancer Hematology Centers - Flint
-
Contact:
- Site Public Contact
- Telefoonnummer: 810-762-8038
- E-mail: wstrong@ghci.org
-
Hoofdonderzoeker:
- Elie G. Dib
-
Livonia, Michigan, Verenigde Staten, 48154
- Geschorst
- Hope Cancer Clinic
-
Livonia, Michigan, Verenigde Staten, 48154
- Werving
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hoofdonderzoeker:
- Elie G. Dib
-
Macomb, Michigan, Verenigde Staten, 48044
- Werving
- Henry Ford Saint John Hospital - Macomb Medical
-
Hoofdonderzoeker:
- Elie G. Dib
-
Contact:
- Site Public Contact
- Telefoonnummer: 313-343-3166
- E-mail: kforman1@hfhs.org
-
Pontiac, Michigan, Verenigde Staten, 48341
- Werving
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hoofdonderzoeker:
- Elie G. Dib
-
Pontiac, Michigan, Verenigde Staten, 48341
- Werving
- Michigan Healthcare Professionals Pontiac
-
Hoofdonderzoeker:
- Elie G. Dib
-
Contact:
- Site Public Contact
- Telefoonnummer: 248-858-6215
- E-mail: Emily.Crofts@trinity-health.org
-
Pontiac, Michigan, Verenigde Staten, 48341
- Werving
- Trinity Health IHA Medical Group-Alice Gustafson Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hoofdonderzoeker:
- Elie G. Dib
-
Saginaw, Michigan, Verenigde Staten, 48604
- Geschorst
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, Verenigde Staten, 48601
- Werving
- MyMichigan Medical Center Saginaw
-
Contact:
- Site Public Contact
- Telefoonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hoofdonderzoeker:
- Elie G. Dib
-
Tawas City, Michigan, Verenigde Staten, 48764
- Werving
- MyMichigan Medical Center Tawas
-
Contact:
- Site Public Contact
- Telefoonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hoofdonderzoeker:
- Elie G. Dib
-
West Branch, Michigan, Verenigde Staten, 48661
- Geschorst
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Ypsilanti, Michigan, Verenigde Staten, 48106
- Werving
- Huron Gastroenterology PC
-
Contact:
- Site Public Contact
- Telefoonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hoofdonderzoeker:
- Elie G. Dib
-
Ypsilanti, Michigan, Verenigde Staten, 48197
- Werving
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
Contact:
- Site Public Contact
- Telefoonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hoofdonderzoeker:
- Elie G. Dib
-
-
Minnesota
-
Burnsville, Minnesota, Verenigde Staten, 55337
- Geschorst
- Fairview Ridges Hospital
-
Burnsville, Minnesota, Verenigde Staten, 55337
- Geschorst
- Minnesota Oncology - Burnsville
-
Cambridge, Minnesota, Verenigde Staten, 55008
- Geschorst
- Cambridge Medical Center
-
Coon Rapids, Minnesota, Verenigde Staten, 55433
- Werving
- Mercy Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Hoofdonderzoeker:
- David M. King
-
Edina, Minnesota, Verenigde Staten, 55435
- Geschorst
- Fairview Southdale Hospital
-
Edina, Minnesota, Verenigde Staten, 55435
- Werving
- Minnesota Oncology - Edina
-
Contact:
- Site Public Contact
- Telefoonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Hoofdonderzoeker:
- David M. King
-
Fridley, Minnesota, Verenigde Staten, 55432
- Actief, niet wervend
- Unity Hospital
-
Maple Grove, Minnesota, Verenigde Staten, 55369
- Geschorst
- Fairview Clinics and Surgery Center Maple Grove
-
Maplewood, Minnesota, Verenigde Staten, 55109
- Werving
- Minnesota Oncology Hematology PA-Maplewood
-
Contact:
- Site Public Contact
- Telefoonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Hoofdonderzoeker:
- David M. King
-
Maplewood, Minnesota, Verenigde Staten, 55109
- Geschorst
- Saint John's Hospital - Healtheast
-
Minneapolis, Minnesota, Verenigde Staten, 55407
- Geschorst
- Abbott-Northwestern Hospital
-
Minneapolis, Minnesota, Verenigde Staten, 55415
- Geschorst
- Hennepin County Medical Center
-
Minneapolis, Minnesota, Verenigde Staten, 55454
- Geschorst
- Health Partners Inc
-
Monticello, Minnesota, Verenigde Staten, 55362
- Geschorst
- Monticello Cancer Center
-
New Ulm, Minnesota, Verenigde Staten, 56073
- Geschorst
- New Ulm Medical Center
-
Princeton, Minnesota, Verenigde Staten, 55371
- Geschorst
- Fairview Northland Medical Center
-
Robbinsdale, Minnesota, Verenigde Staten, 55422
- Geschorst
- North Memorial Medical Health Center
-
Rochester, Minnesota, Verenigde Staten, 55905
- Werving
- Mayo Clinic in Rochester
-
Contact:
- Site Public Contact
- Telefoonnummer: 855-776-0015
-
Hoofdonderzoeker:
- Lance C. Pagliaro
-
Saint Louis Park, Minnesota, Verenigde Staten, 55416
- Werving
- Park Nicollet Clinic - Saint Louis Park
-
Contact:
- Site Public Contact
- Telefoonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Hoofdonderzoeker:
- David M. King
-
Saint Paul, Minnesota, Verenigde Staten, 55101
- Werving
- Regions Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Hoofdonderzoeker:
- David M. King
-
Saint Paul, Minnesota, Verenigde Staten, 55102
- Geschorst
- United Hospital
-
Shakopee, Minnesota, Verenigde Staten, 55379
- Geschorst
- Saint Francis Regional Medical Center
-
Stillwater, Minnesota, Verenigde Staten, 55082
- Werving
- Lakeview Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Hoofdonderzoeker:
- David M. King
-
Waconia, Minnesota, Verenigde Staten, 55387
- Geschorst
- Ridgeview Medical Center
-
Willmar, Minnesota, Verenigde Staten, 56201
- Geschorst
- Rice Memorial Hospital
-
Woodbury, Minnesota, Verenigde Staten, 55125
- Werving
- Minnesota Oncology Hematology PA-Woodbury
-
Contact:
- Site Public Contact
- Telefoonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Hoofdonderzoeker:
- David M. King
-
Wyoming, Minnesota, Verenigde Staten, 55092
- Geschorst
- Fairview Lakes Medical Center
-
-
Missouri
-
Ballwin, Missouri, Verenigde Staten, 63011
- Geschorst
- Mercy Oncology and Hematology - Clayton-Clarkson
-
Bolivar, Missouri, Verenigde Staten, 65613
- Geschorst
- Central Care Cancer Center - Bolivar
-
Cape Girardeau, Missouri, Verenigde Staten, 63703
- Werving
- Saint Francis Medical Center
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 573-334-2230
- E-mail: sfmc@sfmc.net
-
Cape Girardeau, Missouri, Verenigde Staten, 63703
- Geschorst
- Mercy Cancer Center - Cape Girardeau
-
Farmington, Missouri, Verenigde Staten, 63640
- Werving
- Parkland Health Center - Farmington
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 314-996-5569
-
Jefferson City, Missouri, Verenigde Staten, 65109
- Geschorst
- MU Health Care Goldschmidt Cancer Center
-
Joplin, Missouri, Verenigde Staten, 64804
- Geschorst
- Freeman Health System
-
Joplin, Missouri, Verenigde Staten, 64804
- Geschorst
- Mercy Hospital Joplin
-
Rolla, Missouri, Verenigde Staten, 65401
- Geschorst
- Mercy Clinic-Rolla-Cancer and Hematology
-
Rolla, Missouri, Verenigde Staten, 65401
- Geschorst
- Phelps Health Delbert Day Cancer Institute
-
Saint Joseph, Missouri, Verenigde Staten, 64506
- Geschorst
- Heartland Regional Medical Center
-
Sainte Genevieve, Missouri, Verenigde Staten, 63670
- Werving
- Sainte Genevieve County Memorial Hospital
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 314-996-5569
-
Springfield, Missouri, Verenigde Staten, 65804
- Geschorst
- Mercy Hospital Springfield
-
Springfield, Missouri, Verenigde Staten, 65807
- Geschorst
- CoxHealth South Hospital
-
St Louis, Missouri, Verenigde Staten, 63128
- Werving
- Mercy Hospital South
-
Hoofdonderzoeker:
- Jay W. Carlson
-
Contact:
- Site Public Contact
- Telefoonnummer: 314-525-6042
- E-mail: Danielle.Werle@mercy.net
-
St Louis, Missouri, Verenigde Staten, 63141
- Werving
- Mercy Hospital Saint Louis
-
Hoofdonderzoeker:
- Jay W. Carlson
-
Contact:
- Site Public Contact
- Telefoonnummer: 314-251-7066
-
St Louis, Missouri, Verenigde Staten, 63109
- Geschorst
- Mercy Infusion Center - Chippewa
-
St Louis, Missouri, Verenigde Staten, 63131
- Werving
- Missouri Baptist Medical Center
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 314-996-5569
-
Sullivan, Missouri, Verenigde Staten, 63080
- Werving
- Missouri Baptist Sullivan Hospital
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 314-996-5569
-
Washington, Missouri, Verenigde Staten, 63090
- Geschorst
- Mercy Hospital Washington
-
-
Nevada
-
Las Vegas, Nevada, Verenigde Staten, 89102
- Geschorst
- OptumCare Cancer Care at Charleston
-
Las Vegas, Nevada, Verenigde Staten, 89183
- Geschorst
- OptumCare Cancer Care at Fort Apache
-
Reno, Nevada, Verenigde Staten, 89502
- Werving
- Renown Regional Medical Center
-
Hoofdonderzoeker:
- Shi-Ming Tu
-
Contact:
- Site Public Contact
- Telefoonnummer: 775-982-5050
- E-mail: Renown-CRD@renown.org
-
-
New Jersey
-
Hackensack, New Jersey, Verenigde Staten, 07601
- Voltooid
- Hackensack University Medical Center
-
Livingston, New Jersey, Verenigde Staten, 07039
- Werving
- Cooperman Barnabas Medical Center
-
Hoofdonderzoeker:
- Saum B. Ghodoussipour
-
Contact:
- Site Public Contact
- Telefoonnummer: 973-322-5200
-
New Brunswick, New Jersey, Verenigde Staten, 08903
- Werving
- Rutgers Cancer Institute of New Jersey
-
Hoofdonderzoeker:
- Saum B. Ghodoussipour
-
Contact:
- Site Public Contact
- Telefoonnummer: 732-235-7356
-
Toms River, New Jersey, Verenigde Staten, 08755
- Werving
- Community Medical Center
-
Hoofdonderzoeker:
- Saum B. Ghodoussipour
-
Contact:
- Site Public Contact
- Telefoonnummer: 732-557-8294
- E-mail: Lennette.Gonzales@rwjbh.org
-
-
New Mexico
-
Albuquerque, New Mexico, Verenigde Staten, 87106
- Werving
- University of New Mexico Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 505-925-0348
- E-mail: HSC-ClinicalTrialInfo@salud.unm.edu
-
Hoofdonderzoeker:
- Amy C. Tarnower
-
-
New York
-
Buffalo, New York, Verenigde Staten, 14263
- Actief, niet wervend
- Roswell Park Cancer Institute
-
-
North Carolina
-
Clinton, North Carolina, Verenigde Staten, 28328
- Werving
- Southeastern Medical Oncology Center-Clinton
-
Contact:
- Site Public Contact
- Telefoonnummer: 919-587-9084
- E-mail: jfields@cancersmoc.com
-
Hoofdonderzoeker:
- Samer S. Kasbari
-
Goldsboro, North Carolina, Verenigde Staten, 27534
- Werving
- Southeastern Medical Oncology Center-Goldsboro
-
Contact:
- Site Public Contact
- Telefoonnummer: 919-587-9084
- E-mail: jfields@cancersmoc.com
-
Hoofdonderzoeker:
- Samer S. Kasbari
-
Jacksonville, North Carolina, Verenigde Staten, 28546
- Werving
- Southeastern Medical Oncology Center-Jacksonville
-
Hoofdonderzoeker:
- Samer S. Kasbari
-
Contact:
- Site Public Contact
- Telefoonnummer: 910-587-9084
- E-mail: jfields@cancersmoc.com
-
Winston-Salem, North Carolina, Verenigde Staten, 27157
- Actief, niet wervend
- Wake Forest University Health Sciences
-
-
Ohio
-
Centerville, Ohio, Verenigde Staten, 45459
- Werving
- Miami Valley Hospital South
-
Contact:
- Site Public Contact
- Telefoonnummer: 937-528-2900
- E-mail: clinical.trials@daytonncorp.org
-
Hoofdonderzoeker:
- Tarek M. Sabagh
-
Centerville, Ohio, Verenigde Staten, 45459
- Actief, niet wervend
- Dayton Physicians LLC-Miami Valley South
-
Dayton, Ohio, Verenigde Staten, 45409
- Werving
- Miami Valley Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 937-528-2900
- E-mail: clinical.trials@daytonncorp.org
-
Hoofdonderzoeker:
- Tarek M. Sabagh
-
Dayton, Ohio, Verenigde Staten, 45415
- Werving
- Miami Valley Hospital North
-
Contact:
- Site Public Contact
- Telefoonnummer: 937-528-2900
- E-mail: clinical.trials@daytonncorp.org
-
Hoofdonderzoeker:
- Tarek M. Sabagh
-
Dayton, Ohio, Verenigde Staten, 45409
- Werving
- Premier Blood and Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 937-276-8320
-
Hoofdonderzoeker:
- Tarek M. Sabagh
-
Dayton, Ohio, Verenigde Staten, 45415
- Actief, niet wervend
- Dayton Physician LLC - Englewood
-
Findlay, Ohio, Verenigde Staten, 45840
- Actief, niet wervend
- Armes Family Cancer Center
-
Franklin, Ohio, Verenigde Staten, 45005-1066
- Werving
- Atrium Medical Center-Middletown Regional Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 937-528-2900
- E-mail: clinical.trials@daytonncorp.org
-
Hoofdonderzoeker:
- Tarek M. Sabagh
-
Franklin, Ohio, Verenigde Staten, 45005
- Actief, niet wervend
- Dayton Physicians LLC-Atrium
-
Greenville, Ohio, Verenigde Staten, 45331
- Werving
- Miami Valley Cancer Care and Infusion
-
Hoofdonderzoeker:
- Tarek M. Sabagh
-
Contact:
- Site Public Contact
- Telefoonnummer: 937-569-7515
-
Kettering, Ohio, Verenigde Staten, 45409
- Actief, niet wervend
- Greater Dayton Cancer Center
-
Kettering, Ohio, Verenigde Staten, 45429
- Actief, niet wervend
- Kettering Medical Center
-
Springfield, Ohio, Verenigde Staten, 45504
- Geschorst
- Springfield Regional Cancer Center
-
Sylvania, Ohio, Verenigde Staten, 43560
- Werving
- ProMedica Flower Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 419-824-1842
- E-mail: PCIOncResearch@promedica.org
-
Hoofdonderzoeker:
- Jeffrey H. Muler
-
Troy, Ohio, Verenigde Staten, 45373
- Werving
- Upper Valley Medical Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 937-528-2900
- E-mail: clinical.trials@daytonncorp.org
-
Hoofdonderzoeker:
- Tarek M. Sabagh
-
-
Oklahoma
-
Lawton, Oklahoma, Verenigde Staten, 73505
- Werving
- Cancer Centers of Southwest Oklahoma Research
-
Contact:
- Site Public Contact
- Telefoonnummer: 877-231-4440
-
Hoofdonderzoeker:
- Adanma Anji Ayanambakkam Attanathi
-
Oklahoma City, Oklahoma, Verenigde Staten, 73104
- Werving
- University of Oklahoma Health Sciences Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 405-271-8777
- E-mail: ou-clinical-trials@ouhsc.edu
-
Hoofdonderzoeker:
- Adanma Anji Ayanambakkam Attanathi
-
Oklahoma City, Oklahoma, Verenigde Staten, 73120
- Geschorst
- Mercy Hospital Oklahoma City
-
-
Pennsylvania
-
Erie, Pennsylvania, Verenigde Staten, 16505
- Werving
- UPMC Hillman Cancer Center Erie
-
Hoofdonderzoeker:
- Leonard J. Appleman
-
Contact:
- Site Public Contact
- Telefoonnummer: 412-864-7716
- E-mail: ClinicalResearchServices@upmc.edu
-
Greensburg, Pennsylvania, Verenigde Staten, 15601
- Werving
- UPMC Cancer Centers - Arnold Palmer Pavilion
-
Contact:
- Site Public Contact
- Telefoonnummer: 724-838-1900
-
Hoofdonderzoeker:
- Leonard J. Appleman
-
Hershey, Pennsylvania, Verenigde Staten, 17033-0850
- Werving
- Penn State Milton S Hershey Medical Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 717-531-3779
- E-mail: CTO@hmc.psu.edu
-
Hoofdonderzoeker:
- Monika Joshi
-
Monroeville, Pennsylvania, Verenigde Staten, 15146
- Werving
- UPMC Hillman Cancer Center - Monroeville
-
Hoofdonderzoeker:
- Leonard J. Appleman
-
Contact:
- Site Public Contact
- Telefoonnummer: 412-864-7716
- E-mail: ClinicalResearchServices@upmc.edu
-
Philadelphia, Pennsylvania, Verenigde Staten, 19107
- Werving
- Thomas Jefferson University Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 215-600-9151
- E-mail: ONCTrialNow@jefferson.edu
-
Hoofdonderzoeker:
- William J. Tester
-
Philadelphia, Pennsylvania, Verenigde Staten, 19104
- Werving
- University of Pennsylvania/Abramson Cancer Center
-
Hoofdonderzoeker:
- Ronac Mamtani
-
Contact:
- Site Public Contact
- Telefoonnummer: 215-349-8245
- E-mail: PMCancerResearch@pennmedicine.upenn.edu
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15237
- Werving
- UPMC-Passavant Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 412-367-6454
-
Hoofdonderzoeker:
- Leonard J. Appleman
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15243
- Werving
- UPMC-Saint Clair Hospital Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 412-502-3920
-
Hoofdonderzoeker:
- Leonard J. Appleman
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15232
- Werving
- UPMC Hillman Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 412-647-8073
-
Hoofdonderzoeker:
- Leonard J. Appleman
-
Washington, Pennsylvania, Verenigde Staten, 15301
- Werving
- UPMC Cancer Center-Washington
-
Contact:
- Site Public Contact
- E-mail: ecog.rss@jimmy.harvard.edu
-
Hoofdonderzoeker:
- Leonard J. Appleman
-
West Reading, Pennsylvania, Verenigde Staten, 19611
- Werving
- Reading Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 610-988-9323
-
Hoofdonderzoeker:
- Terrence P. Cescon
-
-
South Carolina
-
Charleston, South Carolina, Verenigde Staten, 29425
- Actief, niet wervend
- Medical University of South Carolina
-
-
Texas
-
Dallas, Texas, Verenigde Staten, 75390
- Werving
- UT Southwestern/Simmons Cancer Center-Dallas
-
Contact:
- Site Public Contact
- Telefoonnummer: 214-648-7097
- E-mail: canceranswerline@UTSouthwestern.edu
-
Hoofdonderzoeker:
- Vitaly Margulis
-
Dallas, Texas, Verenigde Staten, 75235
- Werving
- Parkland Memorial Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 214-590-5582
- E-mail: canceranswerline@UTSouthwestern.edu
-
Hoofdonderzoeker:
- Vitaly Margulis
-
Dallas, Texas, Verenigde Staten, 75237
- Geschorst
- UT Southwestern Simmons Cancer Center - RedBird
-
Fort Worth, Texas, Verenigde Staten, 76104
- Werving
- UT Southwestern/Simmons Cancer Center-Fort Worth
-
Contact:
- Site Public Contact
- Telefoonnummer: 214-648-7097
- E-mail: canceranswerline@UTSouthwestern.edu
-
Hoofdonderzoeker:
- Vitaly Margulis
-
Richardson, Texas, Verenigde Staten, 75080
- Werving
- UT Southwestern Clinical Center at Richardson/Plano
-
Contact:
- Site Public Contact
- Telefoonnummer: 972-669-7044
- E-mail: Suzanne.cole@utsouthwestern.edu
-
Hoofdonderzoeker:
- Vitaly Margulis
-
-
Washington
-
Seattle, Washington, Verenigde Staten, 98195
- Werving
- University of Washington Medical Center - Montlake
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-804-8824
-
Hoofdonderzoeker:
- Petros Grivas
-
Seattle, Washington, Verenigde Staten, 98109
- Werving
- Fred Hutchinson Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-804-8824
-
Hoofdonderzoeker:
- Petros Grivas
-
-
West Virginia
-
Charleston, West Virginia, Verenigde Staten, 25304
- Werving
- Vandalia Health/CAMC Institute for Academic Medicine
-
Hoofdonderzoeker:
- Kok Hoe Chan
-
Contact:
- Site Public Contact
- Telefoonnummer: 304-388-9944
- E-mail: CAMCClinicalTrials@vandaliahealth.org
-
-
Wisconsin
-
Appleton, Wisconsin, Verenigde Staten, 54911
- Werving
- ThedaCare Regional Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 920-364-3604
- E-mail: ResearchDept@thedacare.org
-
Hoofdonderzoeker:
- Matthias Weiss
-
Burlington, Wisconsin, Verenigde Staten, 53105
- Werving
- Aurora Cancer Care-Southern Lakes VLCC
-
Contact:
- Site Public Contact
- Telefoonnummer: 414-302-2304
- E-mail: ncorp@aurora.org
-
Hoofdonderzoeker:
- Thomas J. Saphner
-
Eau Claire, Wisconsin, Verenigde Staten, 54701
- Werving
- Marshfield Medical Center-EC Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-782-8581
- E-mail: oncology.clinical.trials@marshfieldresearch.org
-
Hoofdonderzoeker:
- Seth O. Fagbemi
-
Germantown, Wisconsin, Verenigde Staten, 53022
- Werving
- Aurora Health Care Germantown Health Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 414-302-2304
- E-mail: ncorp@aurora.org
-
Hoofdonderzoeker:
- Thomas J. Saphner
-
Grafton, Wisconsin, Verenigde Staten, 53024
- Werving
- Aurora Cancer Care-Grafton
-
Contact:
- Site Public Contact
- Telefoonnummer: 414-302-2304
- E-mail: ncorp@aurora.org
-
Hoofdonderzoeker:
- Thomas J. Saphner
-
Green Bay, Wisconsin, Verenigde Staten, 54311
- Werving
- Aurora BayCare Medical Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 414-302-2304
- E-mail: ncorp@aurora.org
-
Hoofdonderzoeker:
- Thomas J. Saphner
-
Kenosha, Wisconsin, Verenigde Staten, 53142
- Werving
- Aurora Cancer Care-Kenosha South
-
Contact:
- Site Public Contact
- Telefoonnummer: 414-302-2304
- E-mail: ncorp@aurora.org
-
Hoofdonderzoeker:
- Thomas J. Saphner
-
Marinette, Wisconsin, Verenigde Staten, 54143
- Werving
- Aurora Bay Area Medical Group-Marinette
-
Contact:
- Site Public Contact
- Telefoonnummer: 414-302-2304
- E-mail: ncorp@aurora.org
-
Hoofdonderzoeker:
- Thomas J. Saphner
-
Marshfield, Wisconsin, Verenigde Staten, 54449
- Werving
- Marshfield Medical Center-Marshfield
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-782-8581
- E-mail: oncology.clinical.trials@marshfieldresearch.org
-
Hoofdonderzoeker:
- Seth O. Fagbemi
-
Milwaukee, Wisconsin, Verenigde Staten, 53209
- Werving
- Aurora Cancer Care-Milwaukee
-
Contact:
- Site Public Contact
- Telefoonnummer: 414-302-2304
- E-mail: ncorp@aurora.org
-
Hoofdonderzoeker:
- Thomas J. Saphner
-
Milwaukee, Wisconsin, Verenigde Staten, 53215
- Werving
- Aurora Saint Luke's Medical Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 414-302-2304
- E-mail: ncorp@aurora.org
-
Hoofdonderzoeker:
- Thomas J. Saphner
-
Milwaukee, Wisconsin, Verenigde Staten, 53233
- Werving
- Aurora Sinai Medical Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 414-302-2304
- E-mail: ncorp@aurora.org
-
Hoofdonderzoeker:
- Thomas J. Saphner
-
Minocqua, Wisconsin, Verenigde Staten, 54548
- Werving
- Marshfield Medical Center - Minocqua
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-782-8581
- E-mail: oncology.clinical.trials@marshfieldresearch.org
-
Hoofdonderzoeker:
- Seth O. Fagbemi
-
Mukwonago, Wisconsin, Verenigde Staten, 53149
- Werving
- ProHealth D N Greenwald Center
-
Contact:
- Site Public Contact
- E-mail: research.institute@phci.org
-
Hoofdonderzoeker:
- Timothy R. Wassenaar
-
New Richmond, Wisconsin, Verenigde Staten, 54017
- Geschorst
- Cancer Center of Western Wisconsin
-
Oconomowoc, Wisconsin, Verenigde Staten, 53066
- Werving
- ProHealth Oconomowoc Memorial Hospital
-
Hoofdonderzoeker:
- Timothy R. Wassenaar
-
Contact:
- Site Public Contact
- Telefoonnummer: 262-928-7878
-
Oshkosh, Wisconsin, Verenigde Staten, 54904
- Werving
- Vince Lombardi Cancer Clinic - Oshkosh
-
Contact:
- Site Public Contact
- Telefoonnummer: 414-302-2304
- E-mail: ncorp@aurora.org
-
Hoofdonderzoeker:
- Thomas J. Saphner
-
Racine, Wisconsin, Verenigde Staten, 53406
- Werving
- Aurora Cancer Care-Racine
-
Contact:
- Site Public Contact
- Telefoonnummer: 414-302-2304
- E-mail: ncorp@aurora.org
-
Hoofdonderzoeker:
- Thomas J. Saphner
-
Rice Lake, Wisconsin, Verenigde Staten, 54868
- Werving
- Marshfield Medical Center-Rice Lake
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-782-8581
- E-mail: oncology.clinical.trials@marshfieldresearch.org
-
Hoofdonderzoeker:
- Seth O. Fagbemi
-
Sheboygan, Wisconsin, Verenigde Staten, 53081
- Werving
- Vince Lombardi Cancer Clinic-Sheboygan
-
Contact:
- Site Public Contact
- Telefoonnummer: 414-302-2304
- E-mail: ncorp@aurora.org
-
Hoofdonderzoeker:
- Thomas J. Saphner
-
Stevens Point, Wisconsin, Verenigde Staten, 54482
- Werving
- Marshfield Medical Center-River Region at Stevens Point
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-782-8581
- E-mail: oncology.clinical.trials@marshfieldresearch.org
-
Hoofdonderzoeker:
- Seth O. Fagbemi
-
Summit, Wisconsin, Verenigde Staten, 53066
- Werving
- Aurora Medical Center in Summit
-
Contact:
- Site Public Contact
- Telefoonnummer: 414-302-2304
- E-mail: ncorp@aurora.org
-
Hoofdonderzoeker:
- Thomas J. Saphner
-
Two Rivers, Wisconsin, Verenigde Staten, 54241
- Werving
- Vince Lombardi Cancer Clinic-Two Rivers
-
Contact:
- Site Public Contact
- Telefoonnummer: 414-302-2304
- E-mail: ncorp@aurora.org
-
Hoofdonderzoeker:
- Thomas J. Saphner
-
Waukesha, Wisconsin, Verenigde Staten, 53188
- Werving
- ProHealth Waukesha Memorial Hospital
-
Hoofdonderzoeker:
- Timothy R. Wassenaar
-
Contact:
- Site Public Contact
- Telefoonnummer: 262-928-7632
-
Waukesha, Wisconsin, Verenigde Staten, 53188
- Werving
- UW Cancer Center at ProHealth Care
-
Hoofdonderzoeker:
- Timothy R. Wassenaar
-
Contact:
- Site Public Contact
- Telefoonnummer: 262-928-5539
- E-mail: Chanda.miller@phci.org
-
Waupaca, Wisconsin, Verenigde Staten, 54981
- Werving
- ThedaCare Cancer Care - Waupaca
-
Contact:
- Site Public Contact
- Telefoonnummer: 920-364-3605
- E-mail: ResearchDept@thedacare.org
-
Hoofdonderzoeker:
- Matthias Weiss
-
Wauwatosa, Wisconsin, Verenigde Staten, 53226
- Werving
- Aurora Cancer Care-Milwaukee West
-
Contact:
- Site Public Contact
- Telefoonnummer: 414-302-2304
- E-mail: ncorp@aurora.org
-
Hoofdonderzoeker:
- Thomas J. Saphner
-
West Allis, Wisconsin, Verenigde Staten, 53227
- Werving
- Aurora West Allis Medical Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 414-302-2304
- E-mail: ncorp@aurora.org
-
Hoofdonderzoeker:
- Thomas J. Saphner
-
Weston, Wisconsin, Verenigde Staten, 54476
- Werving
- Marshfield Medical Center - Weston
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-782-8581
- E-mail: oncology.clinical.trials@marshfieldresearch.org
-
Hoofdonderzoeker:
- Seth O. Fagbemi
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
STEP 1 REGISTRATION AND RANDOMIZATION
-
Patients must be >= 18 years of age
-
Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible
-
Patient must have a diagnosis of high grade upper tract urothelial carcinoma expected within 14 weeks (98 days) prior to registration/randomization with one of the following:
-
Biopsy (gold standard, preferred) and either upper urinary tract mass on cross-sectional imaging or tumor directly visualized during upper urinary tract endoscopy
-
High grade cytology and clinically estimated invasive upper urinary tract mass on cross-sectional imaging (e.g., including presence of tumor-related hydronephrosis) or tumor directly visualized during upper urinary tract endoscopy
-
NOTE: Universal histologic testing of UTUC with additional studies, such as immunohistochemistry and/or microsatellite instability, is strongly recommended to identify patients with high probability of Lynch-related or other germline mutation related cancers whom clinicians should refer for genetic counseling and germline testing (this is not required for eligibility)
- Due to the anatomy of upper urinary tract and lack of muscularis propria, pathologic evidence of cT2 on biopsy is usually not possible
-
-
-
Patients must not have any component of small cell/neuroendocrine carcinoma. Other histologic subtypes (variants) are permitted provided the half or predominant (>= 50%) subtype is conventional urothelial carcinoma
-
Leukocytes >= 3,000/mcL (obtained =< 14 days prior to registration/randomization)
-
Platelets >= 100,000/mcL (obtained =< 14 days prior to registration/randomization)
-
Total bilirubin =< 1.2 mg/dL (or ≤ 2 mg/dL for patients with Gilbert's disease)
-
Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2 x institutional ULN (obtained =< 14 days prior to registration/randomization)
-
Hemoglobin (Hgb) >= 9 g/dL (obtained =< 14 days prior to registration/randomization)
- NOTE: Packed red blood transfusion is allowed to achieve this parameter as per treating investigator
-
Patients must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy. A patient of childbearing potential is defined as any patient, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
-
Patients of childbearing potential and sexually active patients must not expect to conceive or father children, either by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse from the time of registration, while on study treatment and for at least 6 months after the last dose of protocol treatment
-
Patients must have no evidence of metastatic disease or clinically enlarged regional lymph nodes (>= 1.5 cm short axis) on imaging required within 28 days prior to registration (Non-regional findings >=1.5 cm short axis that in the opinion of the investigator are not concerning for involvement based on radiographic characteristics, chronicity, avidity on positron emission tomography (PET) scan or other imaging or other criteria can be eligible based on investigator discretion).
- NOTE: Patients with elevated alkaline phosphatase, calcium or suspicious bone pain/tenderness can also undergo baseline bone scan to evaluate for bone metastasis at the discretion of local provider.
-
Patient must meet below criteria for prior/current malignancy history:
-
Non-urothelial cancer malignancy history:
-
Patient must not have another active (or within two years) second malignancy other than resected non-melanoma skin cancers, resected in situ breast, cervical or other in situ carcinoma, and either clinically insignificant per the investigator (e.g. =< Gleason 3+4) on active surveillance (or watchful waiting) or previously treated prostate cancer with no rising prostate specific antigen (PSA) and no plan to treat
- NOTE: Patients with prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
-
Urothelial cancer malignancy history:
- Patient may have a history of resectable urothelial cancer as long as patients meet one of the following:
- T0, Ta or Tis at any time
- T1-4a N0 and no evidence of disease (NED) for more than 2 years from the latest therapy [e.g., radical surgery, transurethral resection of bladder tumor (TURBT), radiation, chemotherapy (neoadjuvant or adjuvant, or with radiation)]. Prior systemic immune checkpoint inhibitor is not allowed.
- Patient with history of >= pT4b, N+, and/or M1 UC is not eligible.
- NOTE: Patients in whom concomitant or prior bladder/urethra predominant (>= 50%) urothelial carcinoma have been surgically resected and demonstrated to be only Ta or carcinoma in situ (CIS) (< cT1 N0) are eligible regardless of time elapsed
-
-
-
Patient must not have any uncontrolled illness including, but not limited to, ongoing or active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis testing in line with local practice), symptomatic congestive heart failure (CHF), myocardial infarction (MI) or unstable angina pectoris, significant uncontrolled cardiac arrhythmia, clinically relevant liver cirrhosis, interstitial lung disease, or psychiatric illness/social situations in the three months prior to registration that would limit compliance with study requirements
-
Patient must not have received prior radiation therapy to >= 25% of the bone marrow for other diseases
-
Patient must not have received prior systemic anthracycline therapy
- NOTE: Patients who have received prior intravesical therapy at any time for non-muscle invasive urothelial carcinoma of the bladder are eligible
-
Patient must not have either history of or active autoimmune disease requiring immunosuppressive therapy within 2 years prior to registration/randomization or any history of inflammatory bowel disease (inflammatory bowel disease [IBD], e.g. ulcerative colitis, or Crohn's disease), neuromuscular autoimmune condition, immune-related pneumonitis or interstitial lung disease. Patients with well-controlled hyper/hypothyroidism, celiac controlled by diet alone, diabetes mellitus type I, vitiligo, alopecia, psoriasis, eczema, lichen planus, or similar skin/mucosa condition are eligible
-
Patient must not be on or have used immunosuppressive medication within 14 days prior to the first dose of durvalumab. The following are exceptions to this criterion and are allowed:
- Intranasal, inhaled, intra-auricular, topical steroids, or local steroid injections (e.g. intra-articular injection
- Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent at the time of enrollment
- Steroids as pre-medications for hypersensitivity reactions (e.g. computed tomography [CT] pre-medication)
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months prior to registration/randomization are eligible for this trial
- NOTE: These patients must be stable on their anti-retroviral regimen with evidence of at least two undetectable viral loads within the past 6 months on the same regimen; the most recent undetectable viral load must be within the past 12 weeks. They must have a CD4 count of greater than 250 cells/mcL over the past 6 months on this same anti-retroviral regimen and must not have had a CD4 count < 200 cells/mcL over the past 2 years, unless it was deemed related to the cancer and/or chemotherapy induced bone marrow suppression. They must not be currently receiving prophylactic therapy for an opportunistic infection and must not have had an opportunistic infection within the past 6 months
- NOTE: For patients who have received chemotherapy in the past 6 months, a CD4 count < 250 cells/mcL during chemotherapy is permitted as long as viral loads were undetectable during this same chemotherapy. They must have an undetectable viral load and a CD4 count >= 250 cells/mcL within 7 days of registration/randomization
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- NOTE: Testing for HIV, hepatitis B or hepatitis C is not required unless clinically indicated
-
Patients with a history of hepatitis C virus (HCV) infection must have been treated and have undetectable viral load. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
-
Patient must not have received live attenuated vaccine within 30 days prior to the first dose of durvalumab, while on protocol treatment and within 30 days after the last dose of durvalumab
-
Patient must not have had a major surgical procedure within 28 days prior to registration/randomization
- NOTE: Cystoscopy/ureteroscopy/TURBT, stent placement or nephrostomy tube is not considered major surgery
-
Patient must not have history of allogenic organ transplantation
-
Patient must have a body weight of > 30 kg
-
Patient must have life expectancy of >= 12 weeks
-
Patient must have creatinine clearance > 15 ml/min as estimated by Cockcroft-Gault formula or glomerular filtration rate (GFR) > 15 ml/min/1.73m^2 within 28 days prior to registration/randomization
-
NOTE: Patients will be assigned to cisplatin-ineligible and cisplatin-eligible cohorts based on their creatinine clearance, Eastern Cooperative Oncology Group (ECOG) performance status, and grade (if any) of peripheral neuropathy and/or hearing loss in keeping with recommended cisplatin contraindications. Patients who are cisplatin-eligible will be randomized to either Arm A or Arm B and patients who are cisplatin-ineligible will be registered to Arm C
-
Patients that meet any of the following four criteria will be registered to the cisplatin-ineligible Arm C if they meet other eligibility criteria:
- Creatinine clearance > 15 ml/min and =< 50 ml/min (estimated by Cockcroft-Gault formula) or GFR > 15ml/min/1.73m^2 and ≤ 50 ml/min/1.73 m^2
- Hearing loss >= 3
- Neuropathy >= 2
- ECOG performance status 2
-
In addition, the patient must have an absolute neutrophil count (ANC) >= 1,000/mcL obtained =< 14 days prior to registration
-
Patients that meet all of the following four criteria will be randomized to the cisplatin-eligible Arm A or Arm B:
- Creatinine clearance > 50ml/min (estimated by Cockcroft-Gault formula) or GFR > 50ml/min/1.73m^2
- ECOG performance status 0-1
- Hearing loss grade 0-2
- Neuropathy 0-1
-
In addition, the patient must have an absolute neutrophil count (ANC) >= 1,500/mcL obtained =< 14 days prior to randomization
-
Also, the patient must have left ventricular ejection fraction (LVEF) >= 50% by (either multigated acquisition scan [MUGA] or 2-D echocardiogram) obtained within obtained within 28 days prior to randomization
-
-
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Arm A (durvalumab, chemotherapy)
Patients receive durvalumab IV over 60 minutes on day 1 of chemotherapy cycles 1 and 3. Patients also receive methotrexate IV over 2-3 minutes, vinblastine sulfate IV, doxorubicin IV, cisplatin IV over at least 2 hours on day 1. Treatments repeat every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment, patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery. Patients also undergo tissue biopsy and blood sample collection on study, and CT or MRI throughout the trial. |
Given IV
Andere namen:
Undergo blood sample collection
Andere namen:
Given IV
Andere namen:
Undergo CT
Andere namen:
Undergo MRI
Andere namen:
Undergo surgery Undergo tissue biopsy
Andere namen:
Given IV
Andere namen:
Given Iv
Andere namen:
Given via injection
Andere namen:
Given Iv
Andere namen:
|
|
Actieve vergelijker: Arm B (chemotherapy)
Patients also receive methotrexate IV over 2-3 minutes, vinblastine sulfate IV, doxorubicin IV, cisplatin IV over at least 2 hours on day 1. Treatments repeat every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment, patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery. Patients also undergo tissue biopsy and blood sample collection on study, and CT or MRI throughout the trial. |
Given IV
Andere namen:
Undergo blood sample collection
Andere namen:
Given IV
Andere namen:
Undergo CT
Andere namen:
Undergo MRI
Andere namen:
Undergo surgery Undergo tissue biopsy
Andere namen:
Given Iv
Andere namen:
Given via injection
Andere namen:
Given Iv
Andere namen:
|
|
Experimenteel: Arm C (durvalumab, gemcitabine hydrochloride)
Patients receive durvalumab IV over 60 minutes on day 1 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment, patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery. Patients also undergo tissue biopsy and blood sample collection on study, and CT or MRI throughout the trial. |
Undergo blood sample collection
Andere namen:
Undergo CT
Andere namen:
Undergo MRI
Andere namen:
Given IV
Andere namen:
Undergo surgery Undergo tissue biopsy
Andere namen:
Given IV
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Event-free survival (EFS) (Cisplatin eligible cohort: Arms A and B)
Tijdsspanne: From registration/randomization to the earliest of systemic recurrence outside urinary tract, cancer progression, or death from any cause, assessed up to 5 years
|
Disease progression prior to surgery or omission of surgery due to unresectable tumors, muscle-invasive cancer or disease recurring outside of the bladder, urethra, or contralateral upper tract are considered as events for EFS. |
From registration/randomization to the earliest of systemic recurrence outside urinary tract, cancer progression, or death from any cause, assessed up to 5 years
|
|
Pathologic complete response (pCR) (Cisplatin ineligible cohort: Arm C)
Tijdsspanne: At surgery
|
Will assess pathologic complete response at surgery (pCR, pT0N0/Nx) by local pathology review. Patients who drop out prior to surgery or who have unknown response status will be considered as non-responders. |
At surgery
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
pCR (cohort dat in aanmerking komt voor cisplatine: armen A en B)
Tijdsspanne: Tot 5 jaar
|
Tot 5 jaar
|
|
|
EFS (cisplatin-ineligible cohort: Arm C)
Tijdsspanne: From registration/randomization to the earliest of systemic recurrence outside urinary tract, cancer progression, or death from any cause, assessed up to 5 years
|
Will be characterized using the Kaplan-Meier method. |
From registration/randomization to the earliest of systemic recurrence outside urinary tract, cancer progression, or death from any cause, assessed up to 5 years
|
|
Overall survival (OS) (All Patients)
Tijdsspanne: From registration/randomization to death from any cause, assessed up to 5 years
|
OS will be evaluated by arm, post chemotherapy response (ypCR, stage yp =< T1N0, yp >= T2N0), as well as stage (ypCR and > ypCR) within and across treatment arms. Will be estimated using Kaplan-Meier method. |
From registration/randomization to death from any cause, assessed up to 5 years
|
|
Urothelial cancer-free survival or disease-free survival (All Patients)
Tijdsspanne: From the date of surgery to the earlier of a return of upper tract urothelial cancer (UTUC) or death from any cause, assessed up to 5 years
|
A return of UTUC includes non-muscle invasive recurrences, pathologic T2 or higher muscle-invasive recurrences specifically in the urinary tract, metastatic disease outside the urinary tract, or death. Patients alive without documented UTUC will be censored at the date of last disease assessment. |
From the date of surgery to the earlier of a return of upper tract urothelial cancer (UTUC) or death from any cause, assessed up to 5 years
|
|
Cancer-specific survival (All Patients)
Tijdsspanne: From registration/randomization to death due to cancer; deaths due to other causes will be counted as competing events, assessed up to 5 years
|
Will be analyzed using Gray's method and cumulative incidence estimates will be reported. |
From registration/randomization to death due to cancer; deaths due to other causes will be counted as competing events, assessed up to 5 years
|
|
Renal function outcomes following systemic treatment and following radical nephroureterectomy (All Patients)
Tijdsspanne: Post chemotherapy and post surgery
|
The proportion of patients with renal insufficiency (creatinine [CrCl] < 60 ml/min) post chemotherapy and post nephroureterectomy as well as the proportion of patients with renal function improvement (CrCl < 60 ml/min at baseline and CrCl >= 60 ml/min on study) will be reported along with exact binomial confidence intervals. The distribution of changes in renal function post chemotherapy as well as post surgery from baseline will also be reported. The analysis of renal function outcomes will be performed among patients who receive at least one dose of study therapy. |
Post chemotherapy and post surgery
|
|
Incidence of adverse events (All Patients)
Tijdsspanne: Up to 30 days post surgery
|
Toxicity will be evaluated in all treated patients. |
Up to 30 days post surgery
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Jean H Hoffman-Censits, ECOG-ACRIN Cancer Research Group
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Aminozuren, peptiden en eiwitten
- Eiwitten
- Zwavelverbindingen
- Organische chemicaliën
- Heterocyclische verbindingen, 1-ring
- Heterocyclische verbindingen
- Heterocyclische verbindingen, 2-ring
- Heterocyclische verbindingen, gefuseerd ring
- Onderzoekstechnieken
- Klinische laboratoriumtechnieken
- Diagnostische technieken en procedures
- Diagnose
- Chirurgische procedures, operatief
- Cytologische technieken
- Cytodiagnose
- Koolwaterstoffen
- Koolwaterstoffen, cyclisch
- Koolhydraten
- Alkaloïden
- Polycyclische aromatische koolwaterstoffen
- Koolwaterstoffen, aromatisch
- Polycyclische verbindingen
- Glycosiden
- Indolen
- Antilichamen
- Immunoglobulinen
- Immunoproteïnen
- Bloedeiwitten
- Serum -globulines
- Globulines
- Anorganische chemicaliën
- Chloorverbindingen
- Stikstofverbindingen
- Deoxycytidine
- Cytidine
- Pyrimidine -nucleosiden
- Pyrimidines
- Elementen
- Metalen
- Diagnostische technieken, chirurgisch
- Chemie -technieken, analytisch
- Spectrumanalyse
- Pterins
- Pteridines
- Metalen, zwaar
- Vinca -alkaloïden
- Secologanin tryptamine alkaloïden
- Indol alkaloïden
- Indolizidines
- Indolizines
- Aminopterine
- Antracyclines
- Naftacenes
- Aminoglycosides
- Immunoglobuline -isotypes
- Sulfiden
- Anionen
- Ionen
- Elektrolyten
- Waterstofsulfide
- Platinumverbindingen
- Daunorubicine
- Overgangselementen
- Gemcitabine
- Methotrexaat
- Doxorubicine
- Immunoglobuline G
- Cisplatine
- Vinblastine
- 1,2-diaminocyclohexaanplatina II-citraat
- Biopsie
- Exemplaarbehandeling
- Magnetische resonantiespectroscopie
- durvalumab
- Disulfides
- Platina
- Merphos
- pegfilgrastim
- gepegyleerde granulocyt kolonie-stimulerende factor
Andere studie-ID-nummers
- NCI-2020-09850
- U10CA180820 (Subsidie/contract van de Amerikaanse NIH)
- NCI-2020-09850 (Register-ID: CTRP (Clinical Trial Reporting Program))
- EA8192 (Andere identificatie: CTEP)
- EA8192 (Andere identificatie: ECOG-ACRIN Cancer Research Group)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .